CAS: 935534-47-7; 5-Bromo-4-(Trifluoromethyl)Pyrimidin-2-Amine

该化合物是一种杂环有机化合物,其特点是含有溴和三氟甲基替代物的火水环结构,含有溴和三氟甲基替代物;五处的溴原子和四处的三氟甲基组的存在对其化学反应和物理特性有重大影响;该化合物一般在室内温度下是固体,在极地有机溶剂中表现出中等溶解性;其三氟甲基组会增强亲脂性,并能够影响生物活动,从而引起药物研究的兴趣;二处的氨基组有助于其作为各种生物活性分子合成的一个建筑块的潜力;此外,该化合物还可能由于三氟甲基组的电阻特性而表现出独特的电子特性,这可能影响其在化学反应中的行为;

结构式图片

相似化合物

1785472-42-5 785777-88-0 16075-42-6

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号16075-42-6 2-氨基-4-(三氟甲基)嘧啶 | CAS号1045861-30-0 2-氨基-4-(三氟甲基)嘧啶... | CAS号944401-58-5 2-氨基-4-三氟甲基嘧啶-5... | CAS号16075-42-6 2-氨基-4-(三氟甲基)嘧啶

合成工艺路线路线简述

  • 16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Acetonitrile; 2.5 H,Rt; 4.5 H,Rt
    标题:2-Oxooxazolidinylpyrimidine Derivatives As Pi3K Inhibitors And Their Preparation
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 20 H,Rt
    标题:Preparation Of Dimorpholinopyrimidines For Inhibiting Hamartoma Tumor Cells
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 20 H,Rt
    标题:Identification Of Nvp-Bkm120 As A Potent,Selective,Orally Bioavailable Class I Pi3 Kinase Inhibitor For Treating Cancer
    作者:Burger,Matthew T.; Pecchi,Sabina; Wagman,Allan; Ni,Zhi-Jie; Knapp,Mark; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2011 卷标:2(10) 页码:774-779]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 20 H,Rt
    标题:Pyrimidine Derivatives Used As Pi-3 Kinase Inhibitors And Their Preparation,Pharmaceutical Compositions And Use In The Treatment Of Cancer
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 5 H,50 °C; 15 H,Rt
    标题:Preparation Of Morpholinopurine Compounds As Pi3K And/or Mtor Inhibitors
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Dichloromethane; 2 D,Rt1.2 Reagents: Sodium Hydroxide Solvents: Water; Rt
    标题:Mechanistic Target Of Rapamycin Signaling Pathway Inhibitors,Therapeutic Applications,And Preparation
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 20 H,Rt
    标题:Pyridine Derivatives As Pi3K Inhibitors And Their Preparation,Pharmaceutical Compositions And Use In The Treatment Of Diseases
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Acetonitrile; 2.5 H,Rt; 4.5 H,Rt
    标题:Preparation Of Oxazolidin-2-One Compounds And Uses Thereof As Pi3K Inhibitors
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 20 H,Rt1.2 Reagents: Sodium Hydroxide Solvents: Dichloromethane,Water
    标题:Preparation Of Imidazo[1,2-A]Pyridines And Imidazo[1,2-B]Pyridazines As Pi-3 Kinase Inhibitors
    参考文献:World Intellectual Property Organization]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 5 H,50 °C; 15 H,Rt
    标题:Preparation Of Morpholinopurine Compounds For Inhibiting Pi3K And/or Mtor
    参考文献:Japan]

    16075-42-6 = 935534-47-7
    反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Chloroform; 2 H,Rt
    标题:Preparation Of 2-Morpholino-4,6-Disubstituted Pyrimidine Analogues And Their Application As Anticancer Agents
    参考文献:World Intellectual Property Organization]

    = 935534-47-7 [标题:Reaction Conditions
    标题:Pi 3-Kinase Inhibitors And Methods Of Their Use
    参考文献:United States]

    = 935534-47-7 [标题:Reaction Conditions
    标题:Method Of Inhibiting Hamartoma Tumor Cells
    参考文献:United States
📜4-三氟甲基-2-氨基嘧啶置于n-溴代丁二酰亚胺(Nbs),Sodium Hydroxide体系中,用 氯仿,二氯甲烷 作为反应溶剂,化学反应 20.0H,以82%的收率获得产物2-氨基-5-溴-4-三氟甲基嘧啶
参考文献: Method Of Inhibiting Hamartoma Tumor Cells[fr] Procédé D'Inhibition De Cellules Tumorales D'Hamartome
标题: Method Of Inhibiting Hamartoma Tumor Cells[fr] Procédé D'Inhibition De Cellules Tumorales D'Hamartome
摘要:二咪嗪吡啶是用于抑制错构瘤细胞生长或增殖的有效物质.由于二咪嗪吡啶抑制错构瘤细胞的生长和增殖,因此它们也可用于治疗pten错构瘤综合征.该发明提供的治疗和预防治疗方法是通过向需要的患者施用足够量的二咪嗪吡啶衍生物化合物,以有效抑制错构瘤细胞的生长或增殖.

海关参考信息

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知